About Trinity Biotech Management plans to host meetings with key stakeholders and potential partners as it works to advance the next generation of its recently acquired continuous glucose monitoring (CGM) biosensor technology. Interested parties are invited to reach out for more information by emailing Biosensors@trinitybiotech.com. To learn more about Trinity's CGM, please visit https://cgm.trinitybiotech.com LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Co ...

DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. About Trinity Biotech LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trini ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bios ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bio ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Eric Ri ...

Core Insights - Trinity Biotech plc is on track to achieve approximately $20 million of annualized run-rate EBITDASO on annualized revenues of approximately $75 million by Q2 2025, driven by growth in existing businesses and operational efficiencies [1][2] - The company reported a strong sequential growth of 39% quarter-on-quarter in Point-of-Care revenues, primarily due to the successful rollout of TrinScreen HIV test production [1][2] - Operational efficiencies have led to a 3.6 percentage point increase in gross margin percentage quarter-on-quarter, with further improvements expected through 2024 and into early 2025 [1][2] Business Performance - Total revenues for Q1 2024 were $14.7 million, a slight decrease of 0.8% compared to $14.8 million in Q1 2023 [4][29] - The Point-of-Care portfolio generated revenues of $3.0 million for Q1 2024, reflecting a 38.5% increase from $2.2 million in Q1 2023 [4][6] - TrinScreen HIV sales reached $1.2 million in Q1 2024, with total orders for 2024 supply amounting to $6 million [2][4] Profitability Improvements - The net loss decreased from $5.5 million in Q4 2023 to $3.3 million in Q1 2024, marking a 40% improvement [2][12] - EBITDASO improved by 62% compared to Q4 2023, with expectations for further improvements through 2024 [2][12] - Selling, general and administrative expenses decreased to $7.5 million in Q1 2024 from $8.6 million in Q1 2023, driven by cost-saving initiatives [10][11] Operational Initiatives - The company is implementing a comprehensive transformation plan that includes optimizing supply chains and centralizing corporate services [3][5] - Significant progress has been made in offshoring manufacturing activities, with plans to cease main manufacturing at the Kansas City plant by the end of 2024 [5] - The company has engaged a consultancy for the design of its next-generation Continuous Glucose Monitoring system and is progressing towards a pre-pivotal clinical trial [5] Financial Position - Cash balance increased from $3.7 million at the end of Q4 2023 to $5.8 million at the end of Q1 2024 [19] - The company incurred investing cash outflows of $14.0 million in Q1 2024, primarily related to the acquisition of Waveform assets [19][31] - The renegotiation of the term loan resulted in a reduction of net financial expenses from $2.4 million in Q1 2023 to $0.2 million in Q1 2024 [12][14] Market Compliance - The company received a deficiency letter from Nasdaq regarding the market value of publicly held shares falling below the minimum requirement [21] - A staff determination letter indicated that the company did not regain compliance by the deadline, but it intends to request a hearing to avoid delisting [22][23]

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information | Date: | Thursday, May 23, 2024 | | --- | --- | | Time: | 8:30 AM ET | | United States: | 1-877-407-0784 | | International: | 1- ...

Group 1 - Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors [3] - The company will report its financial results for the first quarter of 2024 on May 23, 2024, at 8:30 AM ET [1] - Trinity Biotech has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc., aiming to develop a range of biosensor devices starting with a continuous glucose monitoring product [3] Group 2 - The company's diagnostic systems include reagents and instrumentation for point-of-care and clinical laboratory segments, used to detect infectious diseases and quantify Haemoglobin A1c levels [3] - Trinity Biotech sells its products directly in the United States, Germany, France, and the U.K., and through a network of international distributors and strategic partners in over 75 countries worldwide [3]

OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Waveform Technologies, Inc. Statement of Assets Acquired and Liabilities Assumed Table of Contents Independent Auditors' Report To the Board of Trinity Biotech Plc Emphasis of matter | | Page No. | | --- | --- | | Independent Auditors' Report | 1 | | Statement of Assets Acquired and Liabilities Assumed as of January 30, 2024 | 2 | | Notes to Statement of Assets Acquired and Liabilities Assumed | 3 - 9 | Opinion We have audited the accompanying Statement of assets acquired and liabilities assume ...